AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...

The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. Study OverviewThis study, officially titled “KEYMAKER-U01 ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Sevabertinib showed promise in early trials for non-squamous non-small-cell lung cancer with HER2 mutations. Read more at ...

Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca's Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a ...

There’s more troubling news about hormone therapy for menopause symptoms: Lung cancer seems more likely to prove fatal in women who are taking estrogen-progestin pills, a study suggests. Hormone users ...

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...

Early access to new cancer drugs, granted accelerated approval by the U.S. Food and Drug Administration (FDA), has provided ...